Stifel analyst Stephen Willey lowered the firm’s price target on Bolt Biotherapeutics (BOLT) to $1 from $1.25 and keeps a Hold rating on the shares following management’s earnings announcement, corporate update, and review of recently-presented Phase 1 dose-escalation data for BDC-3042. The firm believes ISAC conjugates will likely remain a “show-me” story for investors, the analyst noted.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
- Bolt Biotherapeutics Reports Q1 2025 Financial Results
- Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)
- Biotech Alert: Searches spiking for these stocks today
- Bolt Biotherapeutics to host KOL call on BDC-3042 Phase 1 results
- Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting